Prelude Therapeutics PRLD
Prelude Therapeutics FY 2023: net loss $121.8M; diluted EPS −$2.02
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-016016
- Document
- 10-K
- Exhibit 4.4
- Warrants or notes
- Exhibit 4.5
- Warrants or notes
- Exhibit 10.7
- Material contract
- Exhibit 10.13
- Material contract
Key figures from this report
These are the numbers Prelude Therapeutics reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$121.8MAgainst −$115.4M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$2.02Against −$2.44 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$25.3M−17% from $30.6M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$107.1MAgainst −$83.7M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old
- X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
- Akari Therapeutics AKTX public float $15M, Jun 30, 2025
- GeoVax Labs GOVX public float $14M, Jun 30, 2025
- ProPhase Labs PRPH public float $15M, Jun 30, 2025